Sanofi (SNY) Income from Non-Controlling Interests (2009 - 2026)

Sanofi (SNY) posted Income from Non-Controlling Interests of $7.0 million for Q1 2026, up 133.53% sequentially from -$21.0 million in Q4 2025, and down 68.2% YoY from $22.1 million in Q1 2025.

Sanofi (SNY) Income from Non-Controlling Interests (2009 - 2026) Analysis & Trends

Sanofi (SNY) has 18 years of Income from Non-Controlling Interests data on file, last reported at $7.0 million in Q1 2026.

  • Quarterly Income from Non-Controlling Interests fell 68.2% year-over-year to $7.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $26.8 million (down 62.23% YoY) and the FY2025 annual result came in at $44.2 million, down 28.63% from the prior year.
  • Income from Non-Controlling Interests grew to $7.0 million in Q1 2026 per SNY's latest filing, from -$21.0 million in the prior quarter.
  • The five-year high for Income from Non-Controlling Interests was $115.3 million in Q4 2022, with the low at -$82.2 million in Q2 2022.
  • Average Income from Non-Controlling Interests over 5 years is $11.5 million, with a median of $12.8 million recorded in 2024.
  • The widest YoY moves for Income from Non-Controlling Interests: up 907.79% in 2022, down 952.83% in 2022.
  • Sanofi's Income from Non-Controlling Interests stood at $115.3 million in 2022, then tumbled by 102.8% to -$3.2 million in 2023, then jumped by 497.27% to $12.8 million in 2024, then plunged by 263.4% to -$21.0 million in 2025, then soared by 133.53% to $7.0 million in 2026.
  • Business Quant data shows SNY's Income from Non-Controlling Interests at $7.0 million in Q1 2026, -$21.0 million in Q4 2025, and $36.2 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Inc. Minority (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn -
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn -
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn 2.00 Mn
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn 1.00 Mn
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn -3.00 Mn
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn -
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn -
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn 8.00 Mn
9 Novartis Ag 113.45 Bn 113.67 Bn - -
10 Sanofi - - 9.49 Bn 7.02 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 7.02 Mn
Dec 31, 2025 39.58 Mn
Sep 30, 2025 36.24 Mn
Jun 30, 2025 -54.33 Mn
Mar 31, 2025 22.09 Mn
Dec 31, 2024 12.82 Mn
Sep 30, 2024 31.85 Mn
Jun 30, 2024 4.31 Mn
Mar 31, 2024 14.12 Mn
Dec 31, 2023 -3.23 Mn
Sep 30, 2023 14.15 Mn
Jun 30, 2023 -68.60 Mn
Mar 31, 2023 15.03 Mn
Dec 31, 2022 58.15 Mn
Sep 30, 2022 3.02 Mn
Jun 30, 2022 -82.16 Mn
Mar 31, 2022 8.98 Mn
Dec 31, 2021 11.44 Mn
Sep 30, 2021 30.66 Mn
Jun 30, 2021 9.63 Mn